Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ, Janssen JJWM, Cloos J. Tettero JM, et al. Among authors: gjertsen bt. Front Oncol. 2022 Oct 10;12:999822. doi: 10.3389/fonc.2022.999822. eCollection 2022. Front Oncol. 2022. PMID: 36300090 Free PMC article.
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J. Tettero JM, et al. Among authors: gjertsen bt. Haematologica. 2023 Oct 1;108(10):2794-2798. doi: 10.3324/haematol.2022.282639. Haematologica. 2023. PMID: 37021540 Free PMC article. No abstract available.
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Geelen IGP, Gullaksen SE, Ilander MM, Olssen-Strömberg U, Mustjoki S, Richter J, Blijlevens NMA, Smit WM, Gjertsen BT, Gedde-Dahl T, Markevärn B, Koppes MMA, Westerweel PE, Hjorth-Hansen H, Janssen JJWM. Geelen IGP, et al. Among authors: gjertsen bt. Ann Hematol. 2023 Jun;102(6):1395-1408. doi: 10.1007/s00277-023-05199-1. Epub 2023 Apr 29. Ann Hematol. 2023. PMID: 37119314 Clinical Trial.
Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry.
Kleftogiannis D, Gavasso S, Tislevoll BS, van der Meer N, Motzfeldt IKF, Hellesøy M, Gullaksen SE, Griessinger E, Fagerholt O, Lenartova A, Fløisand Y, Schuringa JJ, Gjertsen BT, Jonassen I. Kleftogiannis D, et al. Among authors: gjertsen bt. iScience. 2024 Jun 12;27(7):110261. doi: 10.1016/j.isci.2024.110261. eCollection 2024 Jul 19. iScience. 2024. PMID: 39021803 Free PMC article.
Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
Khan AA, James D, Andresen V, Atkey J, Bradbury R, Cargo C, Dillon R, Gjertsen BT, Goldstone AR, Leach R, Lock D, Narayanan M, Russell N, Verigou EA, Green S, Fielding AK, Falini B. Khan AA, et al. Among authors: gjertsen bt. Am J Hematol. 2024 Oct;99(10):2018-2022. doi: 10.1002/ajh.27301. Epub 2024 Apr 3. Am J Hematol. 2024. PMID: 38567798 No abstract available.
GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells.
Zhang B, Durán PA, Piechaczyk L, Fløisand Y, Safont MMS, Karlsen IT, Fandalyuk Z, Tadele D, Mierlo PV, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM; Bjørn Tore Gjertsen Group; Emmet McCormack Group. Zhang B, et al. Among authors: gjertsen bt. Haematologica. 2018 May 10;Online ahead of print. doi: 10.3324/haematol.2018.189399. Online ahead of print. Haematologica. 2018. Retraction in: Haematologica. 2019 May;104(5):e229. doi: 10.3324/haematol.2019.220533 PMID: 29748445 Free article. Retracted.
Preclinical activity of resazurin in acute myeloid leukaemia.
Ha TQ, Andresen V, Erikstein BS, Popa M, Gullaksen SE, Reikvam H, McCormack E, Gjertsen BT. Ha TQ, et al. Among authors: gjertsen bt. Br J Haematol. 2025 Jan;206(1):109-119. doi: 10.1111/bjh.19872. Epub 2024 Nov 24. Br J Haematol. 2025. PMID: 39582120 Free PMC article.
Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia.
Venanzi A, Cardinali V, Perriello V, Albano F, Cimino G, Martino G, Marra A, Sportoletti P, Andresen V, Gjertsen BT, Sica S, Chiusolo P, Martelli MP, Tiacci E, Falini B. Venanzi A, et al. Among authors: gjertsen bt. Am J Hematol. 2025 Jan;100(1):139-143. doi: 10.1002/ajh.27415. Epub 2024 Jun 22. Am J Hematol. 2025. PMID: 39158266 No abstract available.
287 results